{"id":827950,"date":"2025-03-20T08:05:36","date_gmt":"2025-03-20T12:05:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/"},"modified":"2025-03-20T08:05:36","modified_gmt":"2025-03-20T12:05:36","slug":"ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/","title":{"rendered":"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts"},"content":{"rendered":"<p>        <!--.bwalignl { text-align: left }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwpadr0 { padding-right: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignt { vertical-align: top }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>GE HealthCare launches AI-driven, patient-friendly Invenia<sup \/>ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>The latest Invenia ABUS is designed to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology<\/i><\/li>\n<li><i>Invenia ABUS Premium features new integrated Verisound AI and AI Assistant, which ensure faster and reproducible scanning and reading with extraordinary image quality<\/i><\/li>\n<li><i>The non-invasive ultrasound technology, equipped with a novel Reverse Curve transducer and separate acquisition and reading capabilities, is built to enhance patient care<\/i><\/li>\n<\/ul>\n<p>CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGE HealthCare (Nasdaq: GEHC) announced the launch of Invenia\u2122<sup \/>Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on patients with dense breasts.\n<\/p>\n<p>\nApproximately 71% of cancers occur in dense breasts.<sup>1<\/sup> According to studies across the U.S. and Europe, 40% of women<sup>2<\/sup> and 70% of Asian women<sup>3<\/sup> have dense breast tissue, making them four to six times more likely to receive a breast cancer diagnosis.<sup>4<\/sup> Early detection of breast cancer is critical, yet about one-third<sup>5<\/sup> of cancers in dense breasts may go undetected by a mammogram, as the cancer can be masked within the dense tissue. There is rapidly growing evidence supporting ABUS as a valuable tool for detecting cancer in dense breasts because it provides clearer and more detailed images and has been shown to improve the sensitivity of detecting invasive cancer in dense breasts when added to mammography.<sup>6,7,8,9<\/sup><\/p>\n<p>\n\u201cWomen with dense breasts often face poorer outcomes due to malignancies detected at later, more advanced stages. Invenia ABUS Premium equipped with AI has the potential to optimize clinicians\u2019 screening capabilities, enabling them to detect even small, early-stage cancers with a high degree of confidence in women with dense breasts,\u201d said Karley Yoder, CEO of Comprehensive Care Ultrasound, GE HealthCare. \u201cInvenia ABUS Premium is designed to help deliver the best possible outcomes for patients while also prioritizing the patient experience with features to improve scan speed and enhance comfort during an exam.\u201d\n<\/p>\n<p>\nInvenia ABUS Premium is designed to manage high patient volumes along the breast care pathway, while delivering extraordinary image quality and boosting clinical confidence. The new Verisound\u2122 AI<b \/>tools can help clinicians work smarter and more efficiently, featuring Scan Quality Assessment for immediate qualitative evaluation during the exam for proper breast coverage and positioning, and Auto Nipple Detection for consistent nipple marker positions. The new Fast Scan tool increases scan speed by up to 40%*, while cSound\u2122 Imageformer capabilities automatically create focus at every pixel, ensuring consistent, high-resolution image quality and reproducibility.\n<\/p>\n<p>\nFor fast, streamlined reading, physicians can use Invenia ABUS Viewer with AI Assistant** to quickly review and interpret patient exams either from their practice or remotely. The integration of AI tools** for enhanced review of ABUS 3D datasets harness intelligent algorithms to assist in detecting and characterizing breast lesions. These tools can help improve clinical confidence and reading efficiency, addressing staff shortages.\n<\/p>\n<p>\nThe ABUS Premium\u2019s non-invasive design significantly enhances the patient experience, with a patient experience study showing that 100% of women would recommend an ABUS exam to their best friend.<sup>10<\/sup> This advanced ABUS technology also has the potential to reduce unnecessary biopsies by providing specific image features to distinguish and detect malignant tumors, enabling clinicians to escalate care sooner.<sup>9<\/sup> Additionally, it reduces patient exposure to radiation or contrast injection as it doesn&#8217;t use any iodinated contrast agent or ionizing radiation. The new Reverse Curve\u2122 transducer follows the contour of a woman\u2019s breast anatomy, while selectable compression levels provide personalized comfort during the exam.\n<\/p>\n<p>\n&#8220;As an early adopter of ABUS, I&#8217;ve experienced the entire evolution of this technology. The Invenia ABUS Premium is superior* with its special AI features, which ensure the breast volume is captured and offer automatic nipple annotation, reducing scanning time and streamlining clinical workflow,&#8221; said Athina Vourtsis, MD, PhD, Chief Director and Founder of Athena Medical, Athens, Greece; Founding President of the Hellenic Breast Imaging Society; European Liaison and Member of the Medical Advisory Board of DenseBreast-Info. &#8220;The new Reverse Curve transducer makes the examination more patient friendly, and it is much more comfortable. There has been great improvement in image quality with less shadowing, and the structures behind the area of the nipple are seen more clearly, providing radiologists with greater diagnostic confidence.&#8221;\n<\/p>\n<p>\nInvenia ABUS Premium will be launching in key countries throughout 2025 and received Premarket Approval (PMA) from the U.S. Food and Drug Administration. Invenia ABUS Premium was featured at the 2025 European Congress of Radiology (ECR) and will also be showcased at the National Consortium of Breast Centers (NCoBC) 2025 and 2025 Society of Breast Imaging (SBI) Symposium.\n<\/p>\n<p>\nLearn more about GE HealthCare\u2019s Invenia ABUS Premium here: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Fproducts%2Fultrasound%2Fbreast-ultrasound%2Finvenia-abus-premium&amp;esheet=54226644&amp;newsitemid=20250320743877&amp;lan=en-US&amp;anchor=Invenia+ABUS+Breast+Imaging+Ultrasound+%7C+GE+HealthCare+%28United+States%29&amp;index=1&amp;md5=14367bc613b397d9d582becf850a8fc9\">Invenia ABUS Breast Imaging Ultrasound | GE HealthCare (United States)<\/a><\/p>\n<p><i>*Compared to Invenia<sup>TM<\/sup> ABUS 2.0.<\/i><\/p>\n<p><i>**AI Assistant available third-party tools include QVCAD\u2122, Koios DS\u2122 Breast, BU-CAD\u2122 and MONCAD ABS. Not available in all regions.<\/i><\/p>\n<p><b>About GE HealthCare Technologies Inc.<\/b><\/p>\n<p>\nGE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient\u2019s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.\n<\/p>\n<p>\nGE HealthCare is proud to be among <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ffortune.com%2Franking%2Fworlds-most-admired-companies%2F&amp;esheet=54226644&amp;newsitemid=20250320743877&amp;lan=en-US&amp;anchor=2025+Fortune+World%26%238217%3Bs+Most+Admired+Companies%26%238482%3B&amp;index=2&amp;md5=a29d87d0f5a16f0878937b79dafb521d\">2025 Fortune World\u2019s Most Admired Companies\u2122<\/a>.\n<\/p>\n<p>\nFollow us on<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgehealthcare&amp;esheet=54226644&amp;newsitemid=20250320743877&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=3e0703d322d6db8437e83e0ac860b191\"> LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FGEHealthCare&amp;esheet=54226644&amp;newsitemid=20250320743877&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=f239ace4d54241bfcef532cdad497de8\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FGEHealthCare%2F&amp;esheet=54226644&amp;newsitemid=20250320743877&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=bae9d13f33c51334a58312ccae7fe2f1\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fgehealthcare%2F&amp;esheet=54226644&amp;newsitemid=20250320743877&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=b9b9a334fbf02419a05fb5e3e3f83f3e\">Instagram<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Finsights&amp;esheet=54226644&amp;newsitemid=20250320743877&amp;lan=en-US&amp;anchor=Insights&amp;index=7&amp;md5=d5c496bc2c283a9de08f1302f4563a48\">Insights<\/a> for the latest news, or visit our website<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2F&amp;esheet=54226644&amp;newsitemid=20250320743877&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.gehealthcare.com&amp;index=8&amp;md5=546b1b2fd2bc89d0cae31382ba1de0d9\"> https:\/\/www.gehealthcare.com<\/a> for more information.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>1 <\/sup>Arora N, King TA, Jacks LM., Ann Surg Onc, 2010; 17:S211-18.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>2 <\/sup>Pisano et al. NEJM 2005; 353: 1773.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>3 <\/sup>Ref. Ellison-Loschman, et al, PLOS ONE July 2013.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>4 <\/sup>Boyd NF et al. NEJM 2007; 356: 227\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>5 <\/sup>Mandelson et al. J Natl Cancer Inst 2000; 92:1081-1087.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>6 <\/sup>FDA PMA P110006 summary of safety and effectiveness\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>7 <\/sup>Brem RF, Tab\u00e1r L, et.al. Radiology. 2015 Mar; 274(3): 663-73.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>8 <\/sup>Stempel et.al., Journal of Breast Imaging 2024, Vol XX, No. XX, 1-10.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>9 <\/sup>Wenhui Ren et. al, Elsevier Acad Radiol 2023; 30:S114\u2013S126.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>10 <\/sup>Shah et.al. Journal of Diagnostic Medical Sonography DOI: 10.1177\/8756479313476920 2013.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n\u00a0\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250320743877\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250320743877\/en\/<\/a><\/span><\/p>\n<p><b>GE HealthCare Media Contact<br \/>\n<\/b><br \/>Eric Tatro<br \/>\n<br \/>GE HealthCare<br \/>\n<br \/>+1 312 459 6140<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Eric.Tatro@gehealthcare.com\">Eric.Tatro@gehealthcare.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Illinois<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Managed Care Software Research Other Health General Health Oncology Technology Artificial Intelligence Health Technology Science Biotechnology Health Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250320743877\/en\/1907724\/3\/GE_HealthCare_logo_NEW_March_2023.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts The latest Invenia ABUS is designed to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology Invenia ABUS Premium features new integrated Verisound AI and AI Assistant, which ensure faster and reproducible scanning and reading with extraordinary image quality The non-invasive ultrasound technology, equipped with a novel Reverse Curve transducer and separate acquisition and reading capabilities, is built to enhance patient care CHICAGO&#8211;(BUSINESS WIRE)&#8211; GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia\u2122Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827950","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts The latest Invenia ABUS is designed to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology Invenia ABUS Premium features new integrated Verisound AI and AI Assistant, which ensure faster and reproducible scanning and reading with extraordinary image quality The non-invasive ultrasound technology, equipped with a novel Reverse Curve transducer and separate acquisition and reading capabilities, is built to enhance patient care CHICAGO&#8211;(BUSINESS WIRE)&#8211; GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia\u2122Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on &hellip; Continue reading &quot;GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T12:05:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts\",\"datePublished\":\"2025-03-20T12:05:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/\"},\"wordCount\":1123,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/\",\"name\":\"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-03-20T12:05:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/","og_locale":"en_US","og_type":"article","og_title":"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts - Market Newsdesk","og_description":"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts The latest Invenia ABUS is designed to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology Invenia ABUS Premium features new integrated Verisound AI and AI Assistant, which ensure faster and reproducible scanning and reading with extraordinary image quality The non-invasive ultrasound technology, equipped with a novel Reverse Curve transducer and separate acquisition and reading capabilities, is built to enhance patient care CHICAGO&#8211;(BUSINESS WIRE)&#8211; GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia\u2122Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on &hellip; Continue reading \"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-20T12:05:36+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts","datePublished":"2025-03-20T12:05:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/"},"wordCount":1123,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/","name":"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-03-20T12:05:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250320743877r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-launches-ai-driven-patient-friendly-inveniaabus-premium-to-accelerate-scanning-and-drive-early-cancer-detection-in-dense-breasts\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GE HealthCare launches AI-driven, patient-friendly InveniaABUS Premium to accelerate scanning and drive early cancer detection in dense breasts"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827950"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827950\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827950"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827950"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}